2016-06-08 13:14 CEST (GLOBE NEWSWIRE) —
The first 100 cases constitute a milestone for Episurf. The fact that we can now also compile good clinical follow-up data reflects in the increasing demand for the technology. After 3.5 years, there has not been a single revision, which is quite unprecedented in the field” comments Dr Leif Ryd, Senior Medical Advisor and Board Member, Episurf Medical.
To date, patients in ten European countries have been treated with the Episealer implant, most of them in Episurf’s key markets, Germany and the UK, as well as the Nordic and Benelux regions.
“This is an important milestone for Episurf Medical, following the satisfactory results we have seen in the recent 1-year follow-up data across 24 patients. Strengthened by clinical data showing that patients are truly helped by the Episealer implant, we shall continue working towards mainstreaming Episurf’s patient-specific treatment options as a new standard within the orthopedic industry. In line with our Q1 2016 statement, we are experiencing growth in our business and we anticipate the next 100 implants will come significantly faster than the first 100 as surgeons increase their knowledge about the procedure,” says Rosemary Cunningham Thomas, CEO of Episurf Medical.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
rosemary@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.”
